Bisphosphonates are useful in treatment of disorders with increased osteoclastic activity, but the mechanism by which bisphosphonates act is unknown. We used cultures of chicken osteoclasts to address this issue, and found that 1-hydroxyethylidenediphosphonic acid (EHDP), dichloromethylidenediphosphonic acid (Cl2MDP), or 3-amino-1-hydroxypropylidene-1,1-diphosphonic acid .(APD) all cause direct dose-dependent suppression of osteoclastic activity. Effects are mediated by bone-bound drugs, with 50% reduction of bone degradation occurring at 500 nM to 5 MM of the different agents. Osteoclastic bone-binding capacity decreased by 3040% after 72 h'of bisphosphonate treatment, despite maintenance of cell viability. Significant inhibition of bone resorption in each case is seen only after 24-72 h of treatment.
Introduction
Bisphosphonates (diphosphonates) are compounds characterized by nonhydrolyzable P-C-P groups that bind avidly to hydroxyapatite (1) . These agents are known to impact dramatically upon the skeleton, particularly as inhibitors ofresorption, and are thus effective in the treatment of Paget's disease and hypercalcemia of malignancy (2) . Despite the importance of these drugs in the treatment of hyper-resorptive states, the means by which they block osteoclastic activity remains enigmatic.
Early reports suggested that the antiresorptive effects of bisphosphonates reflect their properties as inhibitors of hydroxyapatite formation and dissolution. On the other hand, direct inhibition of hydroxyapatite crystal growth by 1-hydroxyethylidene-diphosphonic acid (EHDP)' requires a drug concentration of 2 X lo-4 M, while typical absorbed doses of EHDP in treatment of Paget's disease are -0.25 to 6 X l0-5 M/kg body mass. Effective serum concentrations are lower still because the drug is rapidly bound by the skeleton or eliminated in the urine (1) (2) (3) . Consequently, recent studies have focused on the cellular effects of these drugs, which include inhibition of [3H]thymidine incorporation by bone marrowderived macrophages, thought to be related to osteoclasts (4) , as well as effects on migration and transformation of putative osteoclastic precursors (5) , all of which occur at low micromolar or nanomolar bisphosphonate concentrations.
It remains unclear, nevertheless, how these general metabolic effects relate to suppression of bone degradation and, most importantly, whether bisphosphonates target specifically to osteoclasts, as opposed to precursor cells or cells indirectly regulating resorption. To this end, we studied the effects of three representative and widely utilized bisphosphonates, EHDP, C12MDP, and APD, on isolated chicken osteoclasts, and found that each drug impedes the bone resorbing capacity of these cells in a dose-dependent manner. This was confirmed by showing that EDHP reduces the capacity of chicken osteoclasts to acidify the cell-bone interface, a central event in bone resorption, but EHDP, C12MDP and APD have no direct, measurable effect on the activity of the vacuolar proton pump in response to exogenous ATP. In contrast, EHDP, C12MDP or APD suppress [3H]leucine uptake by both osteoclasts and fibroblasts that is eliminated, in fibroblasts but not osteoclasts, by the presence of bone. Thus, the selective effect of bisphosphonates on the osteoclast appears to reflect the avidity with which these drugs bind to bone and the unique capacity ofthis cell to degrade skeletal tissue and thus increase its exposure to the free compounds.
Methods
Unless otherwise specified, reagents were from the Sigma Chemical Co. (St. Louis, MO) , and media were from Gibco Laboratories (Grand Island, NY).
1. Abbreviations used in this paper: a-MEM: Eagle's Minimum Essential Medium, a-modification; APD: 3-amino-l-hydroxypropylidine-1, 1-diphosphonic acid; C12MDP: dichloromethylidinediphosphonic Cell cultures. Osteoclasts were isolated from medullary bone of calcium-starved laying hens, and viable, bone binding cells purified (95-98%) by bone-affinity overnight as described (6, 7 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] mM NH4CI is added, reversing dye quenching that is due to sequestration of dye in acid compartments. Fluorescence of dye alone, in arbitrary units, is indicated as "total dye fluorescence," with fractions of this indicating the degree of quenching (i.e., 0.1 indicates 10% of the dye is quenched), which has been established to be proportional to proton transport (I13).
Proton transport in isolated inside-out vesicles of osteoclast membranes was performed as described (13, 14) . Vesicles were produced by homogenization of 2 X I07osteoclasts in 15 (Table II) . The drugs also reduce protein synthesis by fibroblasts, particularly in the absence of bone (see below).
Bone resorption is a multistep process initiated by osteoclast-matrix attachment, and we found that 72 h treatment with each bisphosphonate (11 MuM) reduced by 30-40% the cell's capacity to bind bone (Table III) . In light, however, ofthe > 90% suppression of resorption generally observed with these concentrations of drugs (Fig. 1) , most of the inhibitory influences of these bisphosphonates could not be accounted for by their impact on cell-matrix attachment. Thus, we turned to another step pivotal to bone degradation, namely acidification of the resorptive micro-environment as osteoclasts mobilize bone mineral by vectorial H+ transport (14) . Using NH4Cl reversible acridine-orange uptake as a measure of proton accumulation and EHDP, which had the highest resorption inhibition to toxicity ratio (Fig. 1, Table I ) as the test compound, we measured acidification by intact osteoclasts on bone. We found that 72 h of EHDP treatment (1.6 MAM) resulted in complete loss of detectable low pH compartments (Fig. 2) . Exposure to 1.6 MuM EHDP for just 2 h, however, did not suppress acidification (not shown). The relatively prolonged bisphosphonate treatment (24-72 h) necessary to detect reduced proton transport by osteoclasts was also consistent with the time course of bone degradation experiments by each bisphosphonate (Fig. 3) . While these data demonstrate that EHDP blocks osteoclastic proton pump activity, they do not prove that the drug targets directly to the H+-ATPase recently shown to be responsible for acidification of the osteoclast's resorptive microenvironment ( 14) . We addressed this issue by incubating inside-out vesicles derived from osteoclast membranes with ATP and acridine orange in the presence of 0-25 Mm EHDP, and found that the bisphosphonate fails to alter ionophore-reversible dye uptake after Mg2"-mediated ATPase activation (Fig. 4) . In similar experiments, C12MDP (12 uM) and APD (6 ,uM), concentrations capable ofinhibiting essentially all acidifying activity of whole cells at 72 h, also failed to measurably affect the activity of the vacuolar proton pump (data not shown). Thus, these bisphosphonates reduce activity of the H' pump, and hence bone resorption, by an indirect mechanism.
Finally, we queried if the three bisphosphonates are delivered to osteoclasts via their resorptive activity, as these drugs bind avidly to hydroxyapatite (3). In the experiments illustrated in Fig. 5 , either unlabeled or [3H]proline-bearing bone was preincubated in 5.6 MM bisphosphonate, washed and added to osteoclast-containing cultures (i.e., only bone-bound drug was added). While each well contained the same quantities of unlabeled and radioactive matrix, the cultures in which resorption of radiolabeled bone were most inhibited were those in which the 3H-bearing matrix was preincubated with the bisphosphonate. In contrast, when unlabeled bone was preincubated with the drug, only partial suppression of resorption occurred. In these experiments, each cell often bound more than one particle of bone (not shown), and hence the partial effect of drug-treated, nonlabeled bone on the resorption of non-drug treated, labeled bone may reflect resorption ofboth types ofparticles by the same cell. In any case, it is clear from this experiment that the osteoclast-inhibiting property of each of the three bisphosphonates tested can be mediated by bone-bound drug, and that the effect is most dramatic when the drug resides on the resorptive surface. The control resorption varies slightly in Fig. 5 B, due to batch-to-batch variation in activity of cells from various animals; however, the same batch of cells is used throughout each experiment, so that the control comparison for each drug's effect is with cells of the same batch.
This conclusion, and the known high affinity of bisphosphonates for hydroxyapatite (3), suggested to us that the apparent specificity of inhibition of osteoclasts by EHDP, Cl2MDP and APD was due to the affinity of the drugs for bone, the osteoclastic substrate, rather than an inherent high susceptibility of this particular cell to these agents. This hypothesis was tested by comparing the effects of bisphosphonates on [3H]-leucine incorporation by fibroblasts in the presence and absence of bone (Table II) . It is clear that, while radioligand incorporation into TCA-precipitable protein by these nonbone resorptive cells was markedly reduced by EHDP, C12MDP or APD in the absence of bone, the inhibition was largely reversed in the presence of mineralized skeletal matrix. The fibroblasts remained, in this case, almost uniformly unattached to the bone (not shown), suggesting that the matrix's protective effect reflects its capacity to bind the drug, thereby isolating it from the nonresorptive cells. (18) . Because these macrophage-based models contain only a single cell type, they permitted us to determine unequivocally whether bisphosphonates directly affect the bone-degrading ability of these cells. Interestingly, we found that while different bisphosphonates inhibit macrophage-mediated resorption by distinct and separate means, when these effects are studied in the presence of bone, they appear to involve mobilization of hydroxyapatite-bound drug.
These experiments, while provocative, are subject to the reasonable criticism that despite the probable ontogenetic relationship of macrophages and osteoclasts, macrophages are not known to participate in bone resorption in vivo. Furthermore, macrophage-mediated bone resorption is relatively inefficient, raising questions as to whether these cells degrade bone by a mechanism similar to that of osteoclasts.
The development of techniques whereby osteoclasts are isolated and maintained in tissue culture permitted us, however, to extend our studies to bona fide resorptive cells. We found that similarly to their effects on macrophages (18), bisphosphonates directly inhibit osteoclastic activity (Fig. 1) . 50% inhibition was seen at 500 nM APD, 1.5 MM EHDP, and 5 ,uM Cl2MDP. In contrast to their effects on mononuclear phagocytes, however, 24-72 h of treatment are required before osteoclastic activity is measurably suppressed (Fig. 3) . Moreover and again, contrasted to the means by which C12MDP blocks macrophage-mediated bone resorption (4), C12MDP and EHDP at moderate (< 11 MM) doses do not kill avian osteoclasts (Table I) . APD inhibits bone resorption at very low concentrations and, as the levels of the drug increase, osteoclast death occurs; in contrast to C12MDP and EHDP, significant APD toxicity is seen at very low concentrations.
The use of isolated osteoclasts has, in recent years, yielded major insights into the cellular mechanisms ofbone resorption (12, 14) . It is known, for example, that cell-matrix attachment is an essential step in the resorptive process (19), and we found that 11 MM EHDP, C12MDP and APD reduce the bone-binding capacity of osteoclasts by 30-40% (Table III) . Of perhaps greater interest is the bisphosphonate effect on the acidifying ability of osteoclasts. Baron and his co-workers have shown that the osteoclast-bone attachment site is an isolated acidic microenvironment (10), and we have recently documented that such acidification is pivotal to bone resorption and under the aegis of a vacuolar H+-ATPase closely resembling that of the intercalated cell of the renal tubule (14) . Indeed, we found that EHDP blocks the acidifying capacity of intact osteoclasts (Fig. 2) .
On the other hand, as reflected by suppression of [3H]leucine incorporation into TCA-precipitable protein (Table II,  osteoclasts) , EHDP, APD, and Cl2MDP are general metabolic inhibitors of osteoclasts. These findings suggested that the agents' impact on cell-bone attachment and acidification may represent altered protein synthesis. Indeed, we noted that despite their capacity to block H+-transport by intact resorptive cells, none of the bisphosphonates reduce ATP-dependent HI accumulation within membrane vesicles bearing the proton pump ( Figs. 2 and 4 ; C12MDP and APD are not shown). Thus, it appears that while bisphosphonates have impact on physiological events central to the resorptive process, these effects are a consequence of general inhibition of cellular metabolism.
In light ofthese findings, we queried whether the inhibitory effects of EHDP, Cl2MDP, and APD on protein synthesis are confined to the osteoclast, and found that fibroblasts are similarly affected (Table II , fibroblasts without bone). At first sight, these observations may stand in contrast to the relative selectivity of the drugs for the skeleton, but such is not the case. It appears, in fact, that it is the avidity with which bisphosphonates bind to bone-mineral that leads to their cell-selective properties. Jung et al. found that at solution concentrations as low as 1 qg/ml, 50-100 mM of EHDP are bound per gram of hydroxyapatite in < 24 h (3). Thus, the skeleton serves as a binding substrate for bisphosphonates, removing them from solution and preventing toxicity to other cell systems in vivo. In support of this conclusion, the toxic effect on non-bone binding fibroblasts is reversed by the presence of bone matrix (Table II, fibroblasts with bone). On the other hand, we now know that the osteoclast enjoys the unique ability to attach to and degrade bone mineral in an isolated microenvironment. A reasonable hypothesis would, thus, hold that EHDP, C12MDP, and APD are released pari passu with mineral mobilization, accumulating locally within the resorptive space at levels sufficient to inhibit osteoclastic bone degradation, a conclusion supported by experiments in which resorption is most efficiently reduced by pretreatment of 3H-labeled but not unlabeled bone with EHDP (Fig. 5) . The inhibitory effects confined to osteoclasts in vivo would therefore reflect the agent's affinity to bind to bone mineral, as well as its toxicity to the cell's resorptive apparatus.
